Effect of a peptide leukotriene receptor antagonist, ONO-1078, on guinea-pig models of asthma. 1993

N Nakagawa, and T Obata, and T Kobayashi, and Y Okada, and F Nambu, and T Terawaki, and T Furuya, and K Muryobayashi, and M Sawada, and H Aishita
MinĂ¥se Research Institute, Ono Pharmaceutical Co., Ltd., Osaka, Japan.

Peptide leukotrienes have been suggested to play an important role in bronchial asthma. As antigen-induced bronchoconstrictions, airway hyperreactivity, and pulmonary eosinophil accumulation are characteristics of the pathology of asthma, we investigated the effect of a peptide leukotriene receptor antagonist, ONO-1078, on these responses using guinea-pig models of asthma. Oral administration of ONO-1078 (3 mg/kg) significantly inhibited slow-reacting substance of anaphylaxis-mediated bronchoconstriction induced by i.v. administered ovalbumin. ONO-1078 (30-100 mg/kg), when administered orally both 1 h before and 4 h after ovalbumin challenge, significantly reduced immediate- and late-phase asthmatic responses, with peak responses occurring immediately and 5-11 h after challenge with inhaled ovalbumin. Oral administration of ONO-1078 significantly reduced the airway hyperreactivity (10-30 mg/kg) and the pulmonary eosinophil accumulation (30-100 mg/kg) observed 4 and 24 h after ovalbumin challenge, respectively. These results suggest that ONO-1078 may be of therapeutic use for bronchial asthma.

UI MeSH Term Description Entries
D006967 Hypersensitivity Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen. Allergy,Allergic Reaction,Allergic Reactions,Allergies,Hypersensitivities,Reaction, Allergic,Reactions, Allergic
D007114 Immunization Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow). Immunologic Stimulation,Immunostimulation,Sensitization, Immunologic,Variolation,Immunologic Sensitization,Immunological Stimulation,Sensitization, Immunological,Stimulation, Immunologic,Immunizations,Immunological Sensitization,Immunological Sensitizations,Immunological Stimulations,Sensitizations, Immunological,Stimulation, Immunological,Stimulations, Immunological,Variolations
D008297 Male Males
D010047 Ovalbumin An albumin obtained from the white of eggs. It is a member of the serpin superfamily. Serpin B14
D010793 Phthalazines Bicyclic heterocyclic compounds containing a BENZENE ring fused to PYRIDAZINE.
D011657 Pulmonary Eosinophilia A condition characterized by infiltration of the lung with EOSINOPHILS due to inflammation or other disease processes. Major eosinophilic lung diseases are the eosinophilic pneumonias caused by infections, allergens, or toxic agents. Eosinophilia, Pulmonary,Eosinophilic Pneumonia,Loeffler Syndrome,Pneumonia, Eosinophilic,Eosinophilias, Pulmonary,Pulmonary Eosinophilias,Simple Pulmonary Eosinophilia,Tropical Eosinophilic Pneumonia,Eosinophilic Pneumonia, Tropical,Eosinophilic Pneumonias,Eosinophilic Pneumonias, Tropical,Pneumonias, Eosinophilic,Pulmonary Eosinophilia, Simple,Simple Pulmonary Eosinophilias,Syndrome, Loeffler,Tropical Eosinophilic Pneumonias
D011738 Pyrilamine A histamine H1 antagonist. It has mild hypnotic properties and some local anesthetic action and is used for allergies (including skin eruptions) both parenterally and locally. It is a common ingredient of cold remedies. Mepyramine,Pyranisamine,Anthisan,Boots Bite & Sting Relief,Kriptin,Mepyramine Maleate,Pyrilamine Maleate,Maleate, Mepyramine,Maleate, Pyrilamine
D001992 Bronchoalveolar Lavage Fluid Washing liquid obtained from irrigation of the lung, including the BRONCHI and the PULMONARY ALVEOLI. It is generally used to assess biochemical, inflammatory, or infection status of the lung. Alveolar Lavage Fluid,Bronchial Lavage Fluid,Lung Lavage Fluid,Bronchial Alveolar Lavage Fluid,Lavage Fluid, Bronchial,Lavage Fluid, Lung,Pulmonary Lavage Fluid,Alveolar Lavage Fluids,Bronchial Lavage Fluids,Bronchoalveolar Lavage Fluids,Lavage Fluid, Alveolar,Lavage Fluid, Bronchoalveolar,Lavage Fluid, Pulmonary,Lavage Fluids, Alveolar,Lavage Fluids, Bronchial,Lavage Fluids, Bronchoalveolar,Lavage Fluids, Lung,Lavage Fluids, Pulmonary,Lung Lavage Fluids,Pulmonary Lavage Fluids
D001993 Bronchodilator Agents Agents that cause an increase in the expansion of a bronchus or bronchial tubes. Bronchial-Dilating Agents,Bronchodilator,Bronchodilator Agent,Broncholytic Agent,Bronchodilator Effect,Bronchodilator Effects,Bronchodilators,Broncholytic Agents,Broncholytic Effect,Broncholytic Effects,Agent, Bronchodilator,Agent, Broncholytic,Agents, Bronchial-Dilating,Agents, Bronchodilator,Agents, Broncholytic,Bronchial Dilating Agents,Effect, Bronchodilator,Effect, Broncholytic,Effects, Bronchodilator,Effects, Broncholytic
D002867 Chromones 1,4-Benzopyrones,Chromone,1,4 Benzopyrones

Related Publications

N Nakagawa, and T Obata, and T Kobayashi, and Y Okada, and F Nambu, and T Terawaki, and T Furuya, and K Muryobayashi, and M Sawada, and H Aishita
July 1994, American journal of respiratory and critical care medicine,
N Nakagawa, and T Obata, and T Kobayashi, and Y Okada, and F Nambu, and T Terawaki, and T Furuya, and K Muryobayashi, and M Sawada, and H Aishita
February 1993, Respiratory medicine,
N Nakagawa, and T Obata, and T Kobayashi, and Y Okada, and F Nambu, and T Terawaki, and T Furuya, and K Muryobayashi, and M Sawada, and H Aishita
October 2002, Acta pharmacologica Sinica,
N Nakagawa, and T Obata, and T Kobayashi, and Y Okada, and F Nambu, and T Terawaki, and T Furuya, and K Muryobayashi, and M Sawada, and H Aishita
November 1996, Arerugi = [Allergy],
N Nakagawa, and T Obata, and T Kobayashi, and Y Okada, and F Nambu, and T Terawaki, and T Furuya, and K Muryobayashi, and M Sawada, and H Aishita
November 1994, American journal of respiratory and critical care medicine,
N Nakagawa, and T Obata, and T Kobayashi, and Y Okada, and F Nambu, and T Terawaki, and T Furuya, and K Muryobayashi, and M Sawada, and H Aishita
March 1993, Prostaglandins, leukotrienes, and essential fatty acids,
N Nakagawa, and T Obata, and T Kobayashi, and Y Okada, and F Nambu, and T Terawaki, and T Furuya, and K Muryobayashi, and M Sawada, and H Aishita
December 2003, Acta pharmacologica Sinica,
N Nakagawa, and T Obata, and T Kobayashi, and Y Okada, and F Nambu, and T Terawaki, and T Furuya, and K Muryobayashi, and M Sawada, and H Aishita
August 2001, Internal medicine (Tokyo, Japan),
N Nakagawa, and T Obata, and T Kobayashi, and Y Okada, and F Nambu, and T Terawaki, and T Furuya, and K Muryobayashi, and M Sawada, and H Aishita
January 1990, International archives of allergy and applied immunology,
N Nakagawa, and T Obata, and T Kobayashi, and Y Okada, and F Nambu, and T Terawaki, and T Furuya, and K Muryobayashi, and M Sawada, and H Aishita
February 2001, Yao xue xue bao = Acta pharmaceutica Sinica,
Copied contents to your clipboard!